SCHEMBL18735945

SCHEMBL18735945

CC(C)SCN1CCN(C)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.38
PHGDH O43175 1/20 0.38
GAA P10253 1/20 0.36
PAOX Q6QHF9 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
ALDH1A1 P00352 3/20 0.33
HTR1A P08908 1/20 0.33
MC4R P32245 1/20 0.33
POLB P06746 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
MAPT P10636 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
LMNA P02545 1/20 0.31
TSHR P16473 2/20 0.31
CYP1A2 P05177 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18481595 0.82 MGLL (0.35) MGLLPHGDHGAAPAOXKDM4E
SCHEMBL1385192 0.80 MEN1 (0.39) ALDH1A1SIGMAR1MAPTLMNATSHR
SCHEMBL19407942 0.79 SLC6A3 (0.37) MGLLPHGDHGAAPAOXALDH1A1
SCHEMBL24079207 0.74 CHRM5 (0.44) PHGDHALDH1A1POLBSIGMAR1LMNA
SCHEMBL872595 0.74 USP2 (0.46) MGLLPHGDHKDM4EGLAALDH1A1
SCHEMBL21919497 0.74 CHRM5 (0.39) KDM4EALDH1A1SIGMAR1TDP1
SCHEMBL16943954 0.72 MGLL (0.42) MGLLPHGDHGAAPAOXKDM4E
SCHEMBL18842903 0.70 MGLL (0.41) MGLLPHGDHGAAPAOXKDM4E
SCHEMBL13403323 0.70 MGLL (0.41) MGLLPHGDHGAAPAOXKDM4E
SCHEMBL12125657 0.69 HTR1A (0.44) MGLLPHGDHKDM4EALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4137572-A1 CHIRAL DESIGN Wave Life Sciences Ltd. (SG) 2023-02-22 EP disclosed
US-10450568-B2 Oligonucleotide compositions and methods thereof WAVE LIFE SCIENCES LTD. (SG) 2019-10-22 US disclosed
WO-2017062862-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2017-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450568-B2 Oligonucleotide compositions and methods thereof RBM17, HNRNPA2B1, HNRNPA1 MGLL 4468/4885PHGDH 4509/4885GAA 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.